Gastrin Secretion After Bariatric Surgery—Response to a Protein-Rich Mixed Meal Following Roux-En-Y Gastric Bypass and Sleeve Gastrectomy: a Pilot Study in Normoglycemic Women

Obesity Surgery

Volumn 26, Issue 7, 2016, Pages 1448-1456

  Grong, Eivind ^a   Græslie, Hallvard ^c   Munkvold, Bjørn ^a   Arbo, Ingerid Brænne ^a   Kulseng, Bård Erik ^a,b   Waldum, Helge L ^a,b   Mårvik, Ronald ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Nord Trøndelag Hospital Trust   (Norway)

Author keywords

Gastrin; Glucagon like peptide 1; Glycemic control; Glycosylated hemoglobin; Insulin; Mixed meal tolerance test; Roux en Y gastric bypass; Sleeve gastrectomy

Indexed keywords

C PEPTIDE; GASTRIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; PROTEIN INTAKE;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DUMPING SYNDROME; FEMALE; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN DIET; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; TACHYCARDIA; AGED; BLOOD; GASTRECTOMY; GASTRIC BYPASS SURGERY; METABOLISM; MIDDLE AGED; OBESITY; PROSPECTIVE STUDY; PROTEIN INTAKE; SECRETION (PROCESS);

ADULT; AGED; BLOOD GLUCOSE; DIETARY PROTEINS; FEMALE; GASTRECTOMY; GASTRIC BYPASS; GASTRINS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MIDDLE AGED; OBESITY; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84948699617     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1985-z     Document Type: Article

References (45)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res ClinPract Elsev Ireland Ltd. 2014;103:137–49.
2. Wild S, Gojka R, Green A, et al. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
3. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
4. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med Elsev Inc. 2009;122:248–56.e5.
5. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.
6. Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidaemia. JAMA. 2013;309:2240–9.
7. Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery: it’s all gastrointestinal factors versus it’s all food restriction. Diabetes Care. 2013;36:S287–91.
8. Romero F, Nicolau J, Flores L, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-en-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26:2231–9.
9. Feldman EJ, Grossman MI. Liver extract and its free amino acids equally stimulate gastric acid secretion. Am J Physiol. 1980;239:G493–6.
10. Richardson CT, Walsh JH, Hicks MI, et al. Studies on the mechanisms of food-stimulated gastric acid secretion in normal human subjects. J Clin Invest. 1976;58:623–31.
11. Håkanson R, Sundler F. Trophic effects of gastrin. Scand J Gastroenterol. 1991;26:130–6.
12. Waldum HL, Sandvik AK, Brenna E, et al. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut. 1991;32:698–701.
13. Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest. 1973;52:1415–26.
14. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf). 2011;201:405–11.
15. Rickels MR, Elahi D. Raising serum gastrin to improve glycemic control in (type 2) diabetes: another limb of the enteroinsular axis? J Clin Endocrinol Metab. 2012;97:3915–6.
16. Waldum HL, Fossmark R, Bakke I, et al. Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol. 2004;39:505–9.
17. Grong E, Arbo IB, Thu OKF, et al. The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats. Surg Endosc. 2015;29:723–33.
18. Bevilacqua M, Dominguez LJ, Righini V, et al. Acute parathyroid hormone increase by oral peptones administration after Roux-en-Y gastric bypass surgery in obese subjects: role of phosphate in the rapid control of parathyroid hormone release. Surg Mosb Inc. 2010;147:655–61.
19. Sillakivi T, Suumann J, Kirsimägi Ü, et al. Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery. Hepatogastroenterology. 2011;60:225–30.
20. Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol. 1985;20:569–76.
21. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64:205–13.
22. Katelaris PH, Seow F, Lin BP, et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut. 1993;34:1032–7.
23. Basso N, Capoccia D, Rizzello M, et al. First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: The gastric hypothesis. Surg Endosc. 2011;25:3540–50.
24. Choi E, Roland JT, Barlow BJ, et al. Cell lineage distribution atlas of the human stomach reveals heterogeneous gland populations in the gastric antrum. Gut. 2014;63:1711–20.
25. Holle GE, Stiegelmeier M, Reidel J, et al. Histologic, immunohistochemical and morphometric study of the mucosa of the total gastric antrum in patients with carcinoma of the stomach. Surg Gynecol Obs. 1993;176:65–72.
26. Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids. Ann Surg. 2005;242:64–73.
27. Erim T, Colak Y, Szomstein S. Gastric carcinoid tumor after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015. doi:10.1016/j.soard.2015.06.016.
28. Arapis K, Cavin JB, Gillard L, et al. Remodeling of the residual gastric mucosa after Roux-en-Y gastric bypass or vertical sleeve gastrectomy in diet-induced obese rats. PLoS One. 2015;10:e0121414.
29. Bödvarsdóttir TB, Hove KD, Gotfredsen CF, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia. 2010;53:2220–3.
30. Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Med Hypothes Elsev Ltd. 2009;73:29–32.
31. Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diab. 2011;2:217–20.
32. Barchetta I, Guglielmi C, Bertoccini L, et al. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetol. 2015;52(5):873–80.
33. Han N, Oh M, Park SM, et al. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Can J Diab Elsevier Ltd. 2015;39:24–8.
34. González-Ortiz M, Martínez-Abundis E, Mercado-Sesma AR, et al. Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108:e11–3.
35. Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2012;97:E2105–8.
36. Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia. 2013;56:22–30.
37. Carswell KA, Vincent RP, Belgaumkar AP, et al. The effect of bariatric surgery on intestinal absorption and transit time. Obes Surg. 2014;24:796–805.
38. Dirksen C, Damgaard M, Bojsen-Møller KN, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil. 2013;25:346–e255.
39. Himpens J, Verbrugghe A, Cadière G-B, et al. Long-term results of laparoscopic Roux-en-Y gastric bypass: evaluation after 9 years. Obes Surg. 2012;22:1586–93.
40. Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725–37.
41. Stenström B, Zhao CM, Tømmerås K, et al. Is gastrin partially responsible for body weight reduction after gastric bypass? Eur Surg Res. 2006;38:94–101.
42. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22:740–8.
43. Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98:4391–9.
44. Jiménez A, Mari A, Casamitjana R, et al. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes. 2014;63:3372–7.
45. Fuchs HF, Broderick RC, Harnsberger CR, et al. Benefits of bariatric surgery do not reach obese men. J Am Coll Surg Am Coll Surg. 2014;219:e2.